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Objective. To evaluate the effect of lesion length on in-stent restenosis (ISR) of vertebral artery (VA) origin stenting.
Methods. We retrospectively analyzed the medical and radiological records of patients receiving VA origin stenting from
March 1999 to June 2005. They were subdivided according to lesion length. ISR was defined as >50% diameter narrowing
in stent.
Results. Eighty symptomatic patients (64 male, mean age 72 years) with 90 lesions treated with balloon expandable tu-
bular coronary stents were enrolled. There were 34 patients with 38 short lesions (length 5 mm, group 1), 37 patients
with 42 medium lesions (length> 5 mm, <10 mm, group 2) and 9 patients with 10 long lesions (length 10 mm, group
3). Eighty seven bare-metal stents and 3 drug-eluting stents were implanted. Repeat angiography was done in 40 lesions
(44%) at 11.7 9.6 months. The ISR rate in group 1, 2, 3 is 21%, 29%, and 50% (p¼ 0.486). Multivariable Cox regres-
sion analysis showed lesion length was the only significant independent predictor of ISR (hazard ratio: 1.19, p¼ 0.039).
Conclusion. ISR of VA origin stenting is common. Lesion length is an important predictor of ISR in VA origin stenting.
Keywords: Vertebral arteries; Transluminal angioplasty; Coronary stent; In-stent restenosis.Introduction
About 25% of ischemic stroke occur in the vertebro-
basilar territory.1,2 Vertebral artery (VA) stenosis
decreases posterior brain perfusion, causing vertebro-
basilar insufficiency (VBI). It is also an important
embolic source to the posterior brain.3e5 The most
frequently involved location is the origin,6 where sur-
gery is not suitable due to poor access. Various surgi-
cal procedures have been described for the treatment
of VA origin stenosis with symptoms refractory to
medical therapy, but all are technically difficult with
high operative mortality and morbidity.7,8
Percutaneous angioplasty with or without stent
placement is an alternative treatment for VA origin
stenosis with high success rates and good initial an-
giographic outcome. However, high restenosis rate
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the restenosis rates reported in the literature were
very high, up to 75 to 100% in one year.9e13 Although
stenting reduces procedure complications by offering
salvage following unsuccessful balloon angioplasty or
angioplasty-induced dissection, the in-stent restenosis
(ISR) rate is still high, ranging from 10 to 45%.14,15 The
pathophysiology and predicating factors of VA stent-
ing restenosis is still unclear.
Lesion length is recognized as an important predic-
tor of ISR in coronary interventions.16 Each 10 mm
increase in stented lesion length is associated with
an absolute increase in percent diameter stenosis of
7.7% at 6 to 9 months follow up.17 This study was de-
signed to evaluate the effect of lesion length on ISR of
VA origin stenting.
Material and Methods
This retrospective study and review of patients’ med-
ical and radiological records was approved by our
institutional review board. Informed consent was
obtained from every patient prior to the procedure,erved.
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phy. The review board of our institute does not re-
quire consent from the patients for the review of
their medical records.
Patients
From March 1999 to June 2005, 80 patients were re-
ferred to a tertiary center for endovascular treatment
due to symptomatic VA origin stenosis refractory to
adequate medication. The clinical and angiographic
data of some patients were report previously.18,19 All
patients presented with typical VBI symptoms such
as severe dizziness or vertigo (56/80, 70%), diplopia
(3/80, 4%), syncope (20/80, 25%), gait disturbance
(9/80, 11%), drop attacks (14/80, 18%), or previous
posterior stroke (17/80, 20%), which was confirmed
by a neurologist. The diagnosis of VA origin stenosis
was made by magnetic resonance angiography, neck
ultrasonography (NUS), or conventional angiography.
Computed tomography (CT) or magnetic resonance
imaging (MRI) was used to document previous poste-
rior stroke when clinically suspected. Other possible
etiologies for the clinical symptoms including cardiac
arrhythmia, postural hypotension, epilepsy, or intra-
cranial neoplasm, were carefully ruled out.
Angiography
Bilateral subclavian and non-selective vertebral artery
angiograms were obtained with 6F JR4 diagnostic
catheter to visualize the true VA ostium, usually taken
at a shallow contralateral cranial angle. Intracranial
continuation to the basilar artery was also confirmed.
Measurements such as diameter stenosis (DS), refer-
ence vessel diameter (RD), and lesion length were
done with a computer-aided digital caliper system
(DCI, Phillips Medical Systems, Eindohoven,
Netherlands). The diameter of a normal ipsilateral
V2 segment was used as reference, similar to the
NASCET method for internal carotid artery stenosis
measurement.20 The indications for stenting were
pre-specified as a) lesion DS> 75% in a VA with
RD> 3.5 mm; or b) DS> 50% in a VA with
RD> 3 mm and contralateral VA occlusion. Lesions
of an artery without continuation to basilar artery or
with severe stenosis beyond V2 segment were
excluded. Patients with severe stenosis in the basilar
artery or its major branches were also excluded. Bilat-
eral VA origin stenting was allowed, as long as the
above-mentioned stenting indications were fulfilled
in individual lesions.Eur J Vasc Endovasc Surg Vol 32, October 2006Stenting
Procedural heparin was given as 70 U/Kg, and acti-
vated clotting time was kept at 250e300 seconds. A
6F JR4 guiding catheter was placed via femoral sheath
into the proximal subclavian artery without engaging
the vertebral ostium. A 0.014$ coronary angioplasty
guide wire was carefully passed across the stenosis
into distal cervical vertebral artery. Pre-dilatation, if
considered necessary by the operator, was done with
under-sized coronary dilatation balloon. Balloon-
expandable tubular coronary stent was then posi-
tioned at the ostium and deployed at high pressure,
with diameter matched to RD. The goal was to
achieve residual DS< 20%, with complete lesion cov-
erage. Stent length was chosen to secure a margin of at
least 1 mm on both ends of the lesion. Excess stent
length was defined as stent length minus lesion
length. Aspirin 100 mg per day, combined with clopi-
dogrel 75 mg per day or ticlodipine 250 mg twice
a day, were started 3 days prior to stenting, and con-
tinued for 3 months.
Follow-up
All patients were followed for symptom change and
neurological examination with monthly clinic visits.
If new posterior stroke was suspected, CT or MRI
was arranged for documentation. Recurrent VBI
symptoms were carefully recorded and validated by
neurologists. NUS were done at 1 and 6 months
post stenting by an independent neurologist. If reste-
nosis was suspected, angiography was mandated to
confirm the diagnosis. Vertebral angiogram was also
obtained in patients undergoing angiographic work-
up or intervention for other vascular territories, but
no systematic angiographic follow-up was planned
in the protocol. Angiographic ISR was defined as
DS> 50% within the stented segment.
Statistical analysis
All continuous data were expressed as mean stan-
dard deviation. Comparisons between groups for con-
tinuous data were made using ANOVAwith post-hoc
analysis or Kruskal-Wallis one-way ANOVA. Differ-
ences between proportions were assessed by chi-
square test or Fisher exact test. Multivariate Cox
regression analysis with stepwise subset selection
was performed to identify the risk factors of restenosis.
The risk factors for analysis included age, sex, bilateral
disease, hypertension, diabetes mellitus, hyperlipid-
emia, smoking, RD, lesion length, stent length, and
381Impact of Lesion Length on Restenosis of VA Stentingexcess stent length. The entry and removal probability
of stepwise selection was 0.1 and 0.2, respectively. A p
value <0.05 is considered significant.
Results
Patient characteristics
Eighty symptomatic patients (64 male, mean age 72
years, range 54 to 91) with 90 lesions treated with
balloon expandable tubular coronary stents were
enrolled in this study. There were 34 patients with 38
short lesions (lesion length 5 mm, group 1), 37 pa-
tients with 42 medium lesions (lesion length> 5 mm,
<10 mm, group 2) and 9 patients with 10 long lesions
(lesion length 10 mm, group 3). The demographic
data and clinical symptoms are summarized in Table 1,
and no significant differences were found between the
3 groups.
Angiographic results
Technical success rate was 100%. Angiographic mea-
surements were summarized in Table 2. The mean le-
sion length was 6.3 2.6 mm and the stent length was
11.8 3.3 mm. The lesion length in group 1, 2, and 3
was 4.4 0.6 mm, 6.7 1.1 mm, 11.9 3.1 mm
( p< 0.001), and the stent length in group 1, 2, and 3
was 10.8 2.9 mm, 11.4 2.2 mm, 17.0 4.2 mm
( p< 0.001). Group 3 patients had significantly longer
lesion length and stent length than group 1 and 2 pa-
tients (all p< 0.001), and group 2 patients had signif-
icantly longer lesion length than group 1 patients
( p< 0.001). The excess stent length in group 1 was sig-
nificantly greater than that in group 2 ( p< 0.01), but
the stent length were similar in groups 1 and 2
( p¼ 0.288). Group 3 patients had lower pre-treatment
DS than group 1 and 2 patients (86 4% in group 3 vs.
93 6% in group 1, p< 0.01; 86 4% in group 3 vs.
92 5% in group 2, p< 0.05). Pre-dilatation was
Table 1. Patient Characteristics (n[ 80)
Group 1
n¼ 34
Group2
N¼ 37
Group3
n¼ 9
P
Men 25 (74) 30 (81) 9 (100) 0.205
Age, y/o 71 9 73 6 70 10 0.272
Hypertension (%) 24 (71) 28 (76) 7 (78) 0.851
Diabetes (%) 10 (29) 11 (30) 1 (11) 0.505
Hyperlipidemia (%) 19 (56) 19 (51) 4 (44) 0.815
Smoking (%) 16 (47) 19 (51) 5 (56) 0.880
Bilateral disease (%) 9 (26) 14 (38) 3 (33) 0.592
Coronary artery disease (%) 25 (74) 23 (62) 7 (78) 0.484
Carotid disease (%) 22 (65) 22 (59) 6 (67) 0.868
Subclavian artery stenosis (%) 3 (9) 5 (14) 1 (11) 0.823
Previous posterior stroke (%) 3 (9) 8 (22) 3 (33) 0.152performed on 17 lesions (19%). Ninety coronary stents
including 87 bare metal stents and 3 drug eluting
stents were used.
Procedural and clinical follow-up
There was no peri-procedural death. The neurological
complications included 2 (2.5%) peri-procedual poste-
rior strokes and 1 (1.7%) peri-procedural anterior
stroke. One patient developed hypovolemic shock
secondary to massive Dieulafoy’s ulcer bleeding after
the otherwise uneventful stenting. Emergency endos-
copy and hemostasis was performed, and he was sta-
bilized and discharged smoothly with all antiplatelet
medications discontinued. However, a left temporal
aspect visual field defect was noted after shock and
persisted in the follow-up period. The stented right
vertebral artery was found to be totally occluded on
the follow-up angiography 8 months later. Another
patient presented with nystagmus and severe vertigo
just after stent implantation. MRI revealed multiple
acute ischemic infarcts in the cerebellum, left thala-
mus, and bilateral occipital regions. The symptoms
improved within 1 week and no permanent neurolog-
ical sequela remained. The third patient who had an
episode of minor left hemispheric stroke 3 weeks
prior to the procedure suffered from worsening
right-sided weakness on the day after intervention.
MRI revealed recent stroke in the left periventricular
white matter, but no posterior infarction was found.
The condition improved 5 days later with com-
plete neurological recovery. Two patients (2.5%) had
vascular complications including one femoral pseu-
doaneurysm and one shoulder hematoma secondary
to a ruptured thoracoacromial artery branch.
Table 2. Angiographic Measurements (n[ 90)
Group 1
n¼ 38
Group2
n¼ 42
Group3
n¼ 10
P
Location right/left 13/25 23/19 2/8 0.057
RD (mm) 4.0 0.5 4.3 0.7 4.2 1.1 0.332
Lesion length (mm) 4.4 0.6 a,b 6.7 1.1c 11.9 3.1 <0.001
Initial DS (%) 93 6 d 92 5e 86 4 0.015
Stent diameter (mm) 4.0 0.4 4.3 0.5 4.2 1.1 0.243
Stent length (mm) 10.8 2.9b 11.4 2.2c 17.0 4.2 <0.001
Excess stent
length (mm)
6.4 2.9f 4.8 2.1 5.1 2.9 0.022
Maximum deployment
pressure (atm)
16 4 17 3 16 5 0.661
Residual stenosis (%) 0 2 2 4 1 3 0.140
Note.dDS¼ diameter stenosis; RD¼ reference vessel diameter
a p< 0.001 between group1 and group 2
b p< 0.001 between group1 and group 3
c p< 0.001 between group2 and group 3
d p< 0.01 between group1 and group 3
e p< 0.05 between group2 and group 3
f p< 0.01 between group1 and group 2Eur J Vasc Endovasc Surg Vol 32, October 2006
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clinics, except for 1 patient who died 2 months after
stenting due to refractory heart failure following cor-
onary bypass surgery. Seventy-eight patients (97.5%)
were asymptomatic at the mean follow-up time of
37.8 24.4 months. One patient (1.3%) reported recur-
rent dizziness 12 months after stenting. MRI revealed
no evidence of new posterior stroke, but NUS showed
restenosis. Repeat angiography at 14 months reveal
80% ISR and balloon angioplasty was done success-
fully. This patient remained asymptomatic for the
following 45 months.
Angiographic follow-up results
Repeat angiography was performed in 40 lesions
(44%) at 11.7 9.6 months, and ISR was revealed in
11 (28%) lesions, including the case mentioned previ-
ously. All 40 lesions were stented with bare metal
stents. The ISR rates of groups 1, 2 and 3 were 21%,
29%, and 50% respectively ( p¼ 0.486). The percentage
of angiographic follow-up, and mean follow-up time
were comparable in the 3 groups (Table 3). Fig. 1
shows the angiogram of a typical case with ISR. Using
multivariate Cox regression analysis, lesion length
was the only significant independent predictor of
restenosis (hazard ratio: 1.19, p¼ 0.039, Table 4).
Discussion
VA stenosis occurs primarily at the proximal part of
the vessel, and the lesion length and RD are usually
6 and 4 mm.21,22 From the experience gained of coro-
nary stenting,17,23 one would expect a very low ISR
rate. However, the angiographic restenosis rate in
the present study was 28%, which is between those re-
ported by Chastain et al.15 (10%) and Albuquerque
et al.14 (43%). Therefore, high ISR rate remains a major
challenge for VA origin stenting despite the high suc-
cess and low complication rates. The different follow-
up intervals and angiographic follow-up rates may
explain the difference in the ISR rates in VA stenting
series, but another possible reason could be the vary-
ing severity of systemic atherosclerosis. Bilateral VA
disease was noted in 33% of our group, similar to
Table 3. Angiography follow-up
Group 1
n¼ 38
Group2
n¼ 42
Group3
n¼ 10
P
Angiographic
follow-up rate (%)
19 (50) 17 (40) 4 (40) 0.663
Mean following
time (day)
389 274 351 324 186 109 0.302
Restenosis rate (%) 4/19 (21) 5/17 (29) 2/4 (50) 0.486Eur J Vasc Endovasc Surg Vol 32, October 2006that reported in Chastain’s series (36%), and lower
than that in Albuquerque’s cohort (82%). In contrast,
the incidence of concurrent carotid (63%), subclavian
(11%), and coronary (69%) artery stenosis was very
high in the present series.
One of the major findings of the present study is
the influence of lesion length on ISR of VA origin
stenting. The ISR rates increased from 21% in group
1 to 50% in group 3. Although the ISR rate in group
3 was 2.5 fold higher than in group 1, there was no
statistically significance difference between the rates
probably due to the small patients numbers. On mul-
tivariate Cox regression analysis, lesion length was
identified as the only significant independent predic-
tors for ISR. Lesion length has been recognized as an
important determinant of ISR in coronary interven-
tion.17,23 Longer lesions with greater plaque burden
are thought to provide an increased source of smooth
muscle cells that migrate and proliferate to form neo-
intima,16 and this mechanism probably applies simi-
larly in the VA origin stenting.
In this study, stent length and excess stent length
were not related to ISR. The shortest stent available
in our institute is 8 mm in length. So in patients with
very short lesions, the chosen stent is likely to be lon-
ger than enough. Actually, the excess stent length
was higher in group 1 than in group 2, while the stent
length is similar in these 2 groups. This may nullify the
effect of stent length on the ISR rate, as the shortest le-
sions are still covered by stents longer than necessary.
In coronary intervention, studies have shown that
stent length is a less powerful predictor for ISR than
the lesion length per se, especially when drug eluting
stents were used.17,24,25 The relationship of actual stent
length and excess stent length on VA origin ISR needs
further investigation. In coronary artery stenting,
small RD is also a proven predictor for ISR.26,27
Implantation of stainless steel stents invariably results
in neointimal growth, and >50% DS is more likely to
occur in vessels of small caliber. The average RD in
the present study was large, and this may explain
why in the present study RDwas not found to be a sig-
nificantly independent predictor for ISR on multivari-
ate Cox regression analysis ( p¼ 0.055).
Recently, site-specific delivery of cell-cycle inhibi-
tors shows promise in inhibiting neoinitimal hyper-
plasia.28 Polymer-based sirolimus or paclitaxel
eluting stents have been shown to be safe and effec-
tive in reducing ISR in coronary stenting.29,30
Sirolimus-coated stents were shown to reduce the pro-
liferation of smooth muscle cells in a canine basilar
artery model.31 These findings imply that drug elut-
ing stent may inhibit ISR in the VA. However, the
6-month ISR rate was surprisingly high (62.5%) in
383Impact of Lesion Length on Restenosis of VA StentingFig. 1. (A) Angiogram showing a 12mm long 80% diameter stenosis at the orifice of left vertebral artery with reference
diameter of 4 mm. (B) Direct stenting with a 4 15 mm stent (maximal pressure 16 atm). (C) Final appearance of the vessel
after stenting showing 0% residual stenosis. (D) Follow-up angiogram at 3 month showing 70% in-stent restenosis.
(E) Angioplasty with 4 20 mm balloon at 10 atm. (F) Final appearance of the vessel after angioplasty showing <10%
residual stenosis.the first reported series of sirolimus eluting stent for
the treatment of extracranial vertebral artery steno-
sis.32 Further evaluation on the effect of drug eluting
stent in VA origin stenting is mandatory.
The indications of VA origin stenting vary signifi-
cantly in different series.13e15,21,22 As the basilar artery
receives dual supply from 2 VA’s, unilateral VA steno-
sis does not necessarily lead to ischemia of the poste-
rior circulation. Only symptomtic patients confirmed
Table 4. Multivariate Cox Model for Restenosis Risk Factor
Identification
Variable Hazard ratio
[95% CI]
P
Lesion length (mm) 1.19 [1.11, 1.34] 0.039
RD (mm) 0.34 [0.11, 1.02] 0.055
Note.dIncluded variables: age, sex, bilateral vertebral artery dis-
ease, hypertension, diabetes mellitus, hyperlipidemia, smoking,
RD, lesion length,, stent length, and excess stent length; entry and
removal probability of stepwise selection as 0.1 and 0.2, respectively.
CI¼ confidence interval; RD: reference vessel diameter.by a neurologist were treated in our series, with pre-
specified angiographic criteria to identify stenosis in
the dominant or the only existing VA. These criteria
warrant future validation, with physiological modali-
ties such as transcranial Doppler,33 cine MR,34 or
intravascular pressure measurement.19 Most patients
in the present study enjoyed clinical improvement
after intervention. Several studies has demonstrated
that VA angioplasty increased distal VA flow,34 basilar
artery flow,35 and fractional flow reserve of the poste-
rior circulation19 by various modality including phase
contrast MRI,35 transcranial Doppler,34 and pressure-
sensing angioplasty guidewires.19 However, most
of the restenosis remained asymptomatic during
follow-up, which was also observed in other
series.13,14,35 The mechanism of the lack of a convinc-
ing correlation between symptom recurrence and ISR
mandates further study.
There are certain limitations of the present study.
Follow-up angiography was not done systematically,Eur J Vasc Endovasc Surg Vol 32, October 2006
384 Y. H. Lin et al.and the angiographic follow-up rate is relatively low
(44%). This may lead to an underestimated ISR rate,
and bias the statistical analysis. Case number is small
and the stents used are not standardized. Further
study including more patients with routine angio-
graphic follow-up is necessary.
In conclusion, symptomatic VA ostial stenosis can
be treated safely and effectively with coronary inter-
vention techniques and equipments. However, ISR
rate of VA origin stents is rather high, and lesion
length is an important predictor for restenosis.
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